Evidence map›Paper›PMID 37241854›Full record

ArticleMolecules (Basel, Switzerland)2023

Novel Biotinylated Cu(II)-Phenanthroline Complexes: 2D and 3D Cytotoxic Activity and Mechanistic Insight.

Stephen Barrett, Michele De Franco, Chiara Donati, Cristina Marzano, Valentina Gandin, Diego Montagner

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Stephen BarrettDepartment of Chemistry, Maynooth University, W23 NPY6 Maynooth, Ireland.
Michele De FrancoDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.ORCID 0000-0002-3940-3371
Chiara DonatiDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.
Cristina MarzanoDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.ORCID 0000-0003-0565-2596
Valentina GandinDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.ORCID 0000-0003-0442-0670
Diego MontagnerDepartment of Chemistry, Maynooth University, W23 NPY6 Maynooth, Ireland.ORCID 0000-0002-1034-9623

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The interest in the use of copper as a metal scaffold for the development of novel chemotherapeutics has considerably grown in recent years. This is mainly due to the relatively lower toxicity of copper complexes with respect to platinum drugs (i.e., cisplatin), the different mechanisms of action, and the cheaper cost. In the last decades, hundreds of copper-based complexes were developed and screened as anticancer agents, with the antesignanus of all compounds being copper bis-phenanthroline [Cu(phen)

Indexed as

Antineoplastic AgentsCoordination ComplexesBiotinCopperDNAPhenanthrolinesAntineoplastic AgentsBiotinCoordination ComplexesCopperDNAPhenanthrolines3D cell culturesanticancer activitybiotincopper(II) complexes

Identifiers

PMID37241854
PMCPMC10222323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.